CVAC: יתרות מזומנים למניה CureVac Pharma

This cash per share chart demonstrates the liquidity of CureVac N.V. (CVAC), which adheres to ESG standards and bioethics in the development of mRNA drugs. The 2.18 mark characterizes this parameter, given that pricing policy depends on grants from strategic partners. The business specifics are non-cyclical, as demand for innovative vaccines is dictated exclusively by scientific achievements and epidemiology.
פילוחים אנליטיים של חברת CureVac N.V.

CureVac N.V. (CVAC) incurs high costs to maintain ultra-low temperatures during the delivery of mRNA drugs, requiring a significant liquid reserve to ensure supply chain continuity. Calculating this metric by dividing total cash holdings by the number of shares allows for an assessment of the business's internal resilience, making cash per share a key indicator of the company's solvency and survival during periods of macroeconomic instability.